AI Engines For more Details: Perplexity Kagi Labs You
Gastrointestinal Health: Bacillus clausii probiotics have been extensively studied for their ability to restore and maintain gastrointestinal health. They can help regulate bowel movements, reduce symptoms of diarrhea, and alleviate gastrointestinal discomfort. Bacillus clausii is particularly effective in managing acute infectious diarrhea caused by bacterial or viral pathogens.
Antimicrobial Activity: Bacillus clausii produces antimicrobial substances such as bacteriocins and enzymes that inhibit the growth of harmful bacteria in the gut. By competing with pathogenic microorganisms for nutrients and space, Bacillus clausii helps maintain a balanced and healthy gut microbiota. This antimicrobial activity also helps prevent the proliferation of harmful bacteria that can cause gastrointestinal infections.
Immune Modulation: Bacillus clausii probiotics have been shown to modulate the immune system, enhancing both innate and adaptive immune responses. They stimulate the production of immune cells and cytokines, which play a crucial role in defending the body against infections and promoting overall immune function. Bacillus clausii may help strengthen the body's natural defenses and reduce the risk of infections, particularly in individuals with weakened immune systems.
Prevention of Antibiotic-Associated Diarrhea: Bacillus clausii is commonly used as a preventive measure against antibiotic-associated diarrhea (AAD). When antibiotics disrupt the balance of gut microbiota, harmful bacteria can proliferate, leading to diarrhea and gastrointestinal symptoms. Bacillus clausii probiotics help restore gut microbiota balance and reduce the risk of AAD by colonizing the intestines and inhibiting the growth of opportunistic pathogens.
Resilience to Environmental Stress: Bacillus clausii forms spores that are highly resistant to environmental stressors such as heat, acidity, and drying. These spores allow the bacterium to survive the harsh conditions of the gastrointestinal tract and reach the intestines alive, where they can exert their beneficial effects. The resilience of Bacillus clausii spores ensures their viability and efficacy as probiotics.
Support for Digestive Disorders: Bacillus clausii probiotics may provide relief for individuals with various digestive disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and gastroenteritis. They help alleviate symptoms such as abdominal pain, bloating, and irregular bowel movements by restoring gut microbiota balance and promoting gastrointestinal health.
Traveler's Diarrhea Prevention: Bacillus clausii probiotics are commonly recommended for travelers to prevent traveler's diarrhea, a common gastrointestinal illness caused by consuming contaminated food or water. By colonizing the intestines and enhancing gut barrier function, Bacillus clausii helps protect against the pathogens responsible for traveler's diarrhea.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Increases |
| species | Bifidobacterium adolescentis | Increases |
| species | Bifidobacterium bifidum | Increases |
| species | Bifidobacterium breve | Increases |
| species | Bifidobacterium catenulatum | Increases |
| species | Bifidobacterium longum | Increases |
| species | Bifidobacterium pseudocatenulatum | Increases |
| species | Lactobacillus acidophilus | Reduces |
| species | Lactobacillus crispatus | Reduces |
| species | Lactobacillus gasseri | Reduces |
| species | Lactobacillus helveticus | Reduces |
| species | Lactobacillus jensenii | Reduces |
| species | Lactobacillus johnsonii | Reduces |
| species | Lactobacillus kefiranofaciens | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 1.4 | 1.1 | 0.27 |
| ADHD | 0.8 | 1.8 | -1.25 |
| Allergic Rhinitis (Hay Fever) | 1.2 | 0.5 | 1.4 |
| Allergies | 1.6 | 1.8 | -0.13 |
| Allergy to milk products | 0.9 | 0.3 | 2 |
| Alopecia (Hair Loss) | 0.6 | -0.6 | |
| Alzheimer's disease | 1.9 | 1.8 | 0.06 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.9 | 2 | -0.05 |
| Ankylosing spondylitis | 0.9 | 1.6 | -0.78 |
| Anorexia Nervosa | 0.4 | 0.2 | 1 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 2.4 | 1.1 | 1.18 |
| Atherosclerosis | 1.1 | 0.6 | 0.83 |
| Atrial fibrillation | 1.1 | 0.6 | 0.83 |
| Autism | 4.1 | 2.6 | 0.58 |
| Bipolar Disorder | 0.6 | 0.6 | 0 |
| Brain Trauma | 0.3 | 1.4 | -3.67 |
| Carcinoma | 0.6 | 0.6 | 0 |
| Celiac Disease | 3.2 | 0.4 | 7 |
| Cerebral Palsy | 1.2 | -1.2 | |
| Chronic Fatigue Syndrome | 1.2 | 1.1 | 0.09 |
| Chronic Kidney Disease | 0.6 | 0.5 | 0.2 |
| Chronic Lyme | 0.3 | 0.3 | |
| Chronic Urticaria (Hives) | 0.6 | 0.6 | |
| Coagulation / Micro clot triggering bacteria | 0.2 | -0.2 | |
| Colorectal Cancer | 1 | 0.8 | 0.25 |
| Constipation | 0.3 | 0.3 | |
| COVID-19 | 3.8 | 2.9 | 0.31 |
| Crohn's Disease | 3.3 | 1.9 | 0.74 |
| cystic fibrosis | 0.6 | 0.6 | |
| Depression | 4.3 | 4.1 | 0.05 |
| Dermatomyositis | 1.2 | 1.2 | |
| Eczema | 1.1 | 0.3 | 2.67 |
| Endometriosis | 0.3 | 1.9 | -5.33 |
| Eosinophilic Esophagitis | 0.8 | 0.8 | |
| Epilepsy | 2.4 | 2.3 | 0.04 |
| Fibromyalgia | 0.6 | 0.5 | 0.2 |
| Functional constipation / chronic idiopathic constipation | 1.4 | 1.9 | -0.36 |
| gallstone disease (gsd) | 1.4 | 1.4 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | -0.8 | |
| Generalized anxiety disorder | 0.8 | 0.8 | |
| Gout | 0.4 | -0.4 | |
| Graves' disease | 1.3 | 1 | 0.3 |
| Hashimoto's thyroiditis | 0.6 | 1.4 | -1.33 |
| Heart Failure | 0.2 | -0.2 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.6 | 0.6 | 0 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
| hyperglycemia | 1.8 | 0.8 | 1.25 |
| Hyperlipidemia (High Blood Fats) | 0.2 | 2 | -9 |
| hypertension (High Blood Pressure | 1.7 | 1.7 | 0 |
| Hypothyroidism | 0.6 | 0.6 | |
| Hypoxia | 0.5 | 0.6 | -0.2 |
| IgA nephropathy (IgAN) | 0.8 | 0.5 | 0.6 |
| Inflammatory Bowel Disease | 3.6 | 1.7 | 1.12 |
| Insomnia | 1.3 | 1.3 | |
| Intracranial aneurysms | 0.5 | -0.5 | |
| Irritable Bowel Syndrome | 2.6 | 1.9 | 0.37 |
| Juvenile idiopathic arthritis | 0.6 | 0.6 | |
| Liver Cirrhosis | 2 | 1.7 | 0.18 |
| Long COVID | 3.7 | 2.4 | 0.54 |
| Lung Cancer | 0.8 | 0.8 | |
| ME/CFS with IBS | 0.6 | 0.6 | |
| ME/CFS without IBS | 0.6 | 0.6 | |
| Menopause | 0.2 | 0.4 | -1 |
| Metabolic Syndrome | 4.5 | 2.8 | 0.61 |
| Mood Disorders | 4.8 | 5.2 | -0.08 |
| multiple chemical sensitivity [MCS] | 0.5 | 0.6 | -0.2 |
| Multiple Sclerosis | 1.1 | 2.9 | -1.64 |
| Multiple system atrophy (MSA) | 1.3 | 1.2 | 0.08 |
| myasthenia gravis | 0.3 | -0.3 | |
| Neuropathy (all types) | 0.5 | 1.2 | -1.4 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.3 | 0.2 | 10.5 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.6 | |
| Obesity | 3.6 | 2.1 | 0.71 |
| obsessive-compulsive disorder | 1.6 | 0.5 | 2.2 |
| Osteoarthritis | 0.8 | 0.8 | |
| Osteoporosis | 1.7 | 0.5 | 2.4 |
| Parkinson's Disease | 2 | 3.3 | -0.65 |
| Polycystic ovary syndrome | 1.9 | 1.9 | |
| Postural orthostatic tachycardia syndrome | 0.8 | 0.8 | |
| Premenstrual dysphoric disorder | 0.6 | -0.6 | |
| Psoriasis | 1.1 | 2.2 | -1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.2 | 2.3 | -0.05 |
| Rosacea | 0.6 | 1.1 | -0.83 |
| Schizophrenia | 2.2 | 2 | 0.1 |
| Sjögren syndrome | 1 | 0.6 | 0.67 |
| Sleep Apnea | 0.3 | 1.2 | -3 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.6 | 1.6 | |
| Stress / posttraumatic stress disorder | 2.5 | 1.2 | 1.08 |
| Systemic Lupus Erythematosus | 2.2 | 0.9 | 1.44 |
| Tic Disorder | 0.6 | 0.6 | |
| Tourette syndrome | 1.1 | -1.1 | |
| Type 1 Diabetes | 0.4 | 1.1 | -1.75 |
| Type 2 Diabetes | 3.9 | 2.8 | 0.39 |
| Ulcerative colitis | 4 | 1.7 | 1.35 |
| Unhealthy Ageing | 2 | 0.2 | 9 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.